ADAP

ADAP

Adaptimmune is a biotechnology company focused on developing novel cell therapies to treat cancer.
It is a clinical-stage leader specializing in T-cell therapies that target solid tumors, a challenging area of oncology with significant medical need.

$0.03 -0.01 (-14.57%)

Updated: 2025年12月23日 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model ✓ Updated Daily

Investment Opinion: Is ADAP Worth Buying?

Based on the technical and fundamental analysis, ADAP presents an extremely high-risk investment profile that cannot be recommended for purchase.

The stock exhibits catastrophic performance with extreme losses across all timeframes and severe downside volatility, significantly underperforming the broader market. While there is some positive revenue growth momentum, this is overshadowed by substantial operating losses, negative cash flows, and poor operational efficiency. Valuation metrics are distorted by unprofitability, and the extreme beta of 2.5 indicates it is approximately 2.5 times more volatile than the market, representing exceptional risk.

Given the combination of catastrophic price erosion, persistent cash burn, inefficient operations, and extreme volatility, the investment case for ADAP is not compelling. The stock's low price may tempt speculative investors, but the fundamental deterioration and high risk characteristics suggest a high probability of continued value destruction.

*Note: This is not investment advice, for reference only.*

CTA Banner

12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, the 12-month outlook for ADAP is exceptionally bearish. The primary catalyst would be a dramatic, unforeseen turnaround in its fundamental operations, such as a major new revenue stream that significantly curbs its cash burn. However, the overwhelming risks are severe, including persistent operating losses, negative cash flow, and extreme volatility (beta of 2.5), which make continued price erosion highly probable. Despite the stark disconnect between the current price of $0.03 and the analyst target of $0.68, the fundamental deterioration suggests this target is improbable, and any investment would be purely speculative with a high risk of total loss.

Wall Street Consensus

Most Wall Street analysts are optimistic about ADAP's outlook over the next 12 months, with consensus target price around $0.68, indicating expectations for further upside potential.

Average Target
$0.68
Based on 3 analysts
Implied Upside
+2167%
vs. Current Price
Analyst Coverage
3
Covering this stock
Price Range
$0 - $2
Analyst target range
Buy Buy
1 (33%)
Hold Hold
1 (33%)
Sell Sell
1 (33%)

Bull vs Bear Case for ADAP

Overall, ADAP has investment merit but also faces multiple challenges. Here are the key factors to consider before investing in this stock.

Bullish Bullish
  • Significant Stock Surge: Stock experienced a remarkable 52% surge on Wednesday indicating strong investor interest.
  • High Volume Call Options: Investors purchased 4,105 call options suggesting bullish bets on future price increases.
  • Potential Turnaround Speculation: Recent 42% stock surge sparks speculation about a possible biotech turnaround.
Bearish Bearish
  • Nasdaq Delisting Announcement: Company announced voluntary delisting from Nasdaq, causing a 62.5% premarket plunge.
  • High Volatility and Declines: Stock fell 16% in one day showing extreme price volatility and negative momentum.
  • Reduced Market Accessibility: Delisting will reduce stock's visibility and accessibility to US investors.
  • Investor Confidence Erosion: Delisting decision signals strategic challenges and erodes market confidence.
Reward Banner

ADAP Technical Analysis

ADAP has experienced catastrophic performance with extreme losses across all measured timeframes. The stock has demonstrated severe downside volatility, significantly underperforming broader market benchmarks.

In the short term, ADAP has collapsed with a 38% monthly decline and devastating 82% quarterly loss, massively underperforming the market by over 85 percentage points. This reflects severe fundamental deterioration and exceptionally weak investor sentiment toward the stock.

Currently trading at $0.03, ADAP sits just above its 52-week low with minimal recovery potential evident from its peak of $0.83, representing technical oversold conditions. However, with a beta of 2.5 indicating extreme volatility and a maximum drawdown nearing 96%, the stock exhibits exceptionally high risk characteristics despite its deeply depressed price level.

📊 Beta
2.49
2.49x market volatility
📉 Max Drawdown
-95.7%
Largest drop in past year
📈 52-Week Range
$0-$1
Price range over past year
💹 1-Year Return
-94.8%
Total return over past year
Period ADAP Return S&P 500
1m -38.4% +4.7%
3m -82.1% +3.5%
6m -88.3% +16.1%
1y -94.8% +15.8%
ytd -95.2% +19.1%

ADAP Fundamental Analysis

ADAP shows mixed revenue performance with Q2 revenue nearly doubling Q1's $7.3 million to $13.7 million, indicating strong top-line growth momentum. However, profitability remains deeply challenged with a gross profit margin of 82% being eroded by high R&D and administrative expenses, resulting in significant operating losses and negative margins across all measures. The company's net loss improved from -$47.6 million in Q1 to -$30.3 million in Q2, but substantial profitability challenges persist.

Financially, ADAP maintains adequate short-term liquidity with current and quick ratios of 1.52 and 1.29 respectively, though the cash ratio of 0.51 suggests limited immediate cash coverage. The debt ratio of 37% appears manageable, but concerning negative cash flow metrics including operating cash flow per share of -$0.13 and negative cash flow to debt ratio indicate ongoing cash burn. The negative interest coverage ratio of -31.5 reflects the company's inability to cover interest expenses from operating earnings.

Operational efficiency metrics reveal significant challenges, with negative return on assets (-23.2%) and return on capital employed (-38.3%) indicating poor asset utilization. The positive return on equity (42.8%) appears distorted likely due to negative equity, while low asset turnover (0.10) and inventory turnover (0.22) suggest inefficient operations. The extended cash conversion cycle of 262 days highlights working capital management inefficiencies impacting cash flow generation.

Quarterly Revenue
$0.0B
2025-06
Revenue YoY Growth
-89.3%
YoY Comparison
Gross Margin
81.7%
Latest Quarter
Free Cash Flow
$-0.2B
Last 12 Months

Revenue & Net Income Trend (2 Years)

See if the company is still growing or starting to slow down

Revenue Breakdown by Segment

Understand if it's a single-product story or multiple business lines

RockFlow Bobby - Your 24/7 AI Investment Partner

Get real-time data and AI-driven investment insights to make smarter investment decisions

Sign up now and get Tesla stock!

Valuation Analysis: Is ADAP Overvalued?

Valuation Level: ADAP trades at a forward PE ratio of -0.11 and an EV/EBITDA of -0.79, indicating the company is currently unprofitable. However, the stock appears inexpensive based on its sales, with a PS ratio of only 0.22. Without a positive earnings base, the negative ratios render traditional PE-based valuation impractical, though the low PS ratio may suggest undervaluation relative to its revenue stream.

Peer Comparison: A direct peer comparison is not possible as industry average data is unavailable. The assessment of ADAP's valuation is therefore based solely on its absolute metrics, lacking the context of industry benchmarks which would be essential for a relative evaluation. This absence of comparative data limits the analytical scope for determining its relative market positioning.

Current PE
1.0×
Latest Quarter
vs. Historical
N/A
5-Year PE Range 1×-44×
vs. Industry Avg
-98.3%
Industry PE ~ 59.9×
EV/EBITDA
-0.8×
Enterprise Value Multiple

Investment Risks

ADAP exhibits extreme volatility risk with a beta of 2.49, indicating it is approximately 2.5 times more volatile than the broader market. This is underscored by a catastrophic 1-year maximum drawdown of -96%, reflecting extreme price erosion and exceptionally high risk for investors holding the stock over this period.

Other risks appear more moderate, as the short interest is very low at 0.19%, suggesting minimal negative speculative pressure from short sellers. However, such extreme price declines could indicate significant liquidity or fundamental business risks not fully captured by the short interest metric alone.

FAQs

Is ADAP a good stock to buy?

Bearish. The stock faces catastrophic technical deterioration with an 82% quarterly loss and extreme volatility (beta 2.5), compounded by a Nasdaq delisting that erodes market accessibility and investor confidence. While revenue growth exists, persistent operational losses and negative cash flows indicate fundamental challenges. Only suitable for extremely risk-tolerant speculators, not long-term investors.

Is ADAP stock overvalued or undervalued?

Based on the provided data, ADAP stock appears undervalued. The primary indicator is its PS ratio of 0.22, which is extremely low and suggests the market is valuing the company at a deep discount to its sales. However, this must be weighed against significant fundamental weaknesses. The negative forward PE and EV/EBITDA confirm the company is unprofitable, while negative cash flows and poor operational efficiency (e.g., ROA of -23.2%) highlight substantial risks. The undervaluation is thus more indicative of the market pricing in these severe profitability and operational challenges than a clear buying opportunity.

What are the main risks of holding ADAP?

Based on the provided information, the key risks of holding ADAP are:

1. Extreme Market Risk: The stock exhibits extreme volatility (beta of 2.49) and has experienced a catastrophic -96% maximum drawdown, indicating a high probability of severe capital erosion relative to the broader market. 2. Severe Profitability and Cash Flow Risk: The company is burning cash with significant operating losses and negative cash flow metrics, threatening its financial sustainability and ability to fund operations without raising additional capital. 3. Fundamental Business Model Risk: Despite recent revenue growth, deeply negative returns on assets (-23.2%) and capital employed (-38.3%) coupled with an inefficient cash conversion cycle (262 days) indicate core operational challenges and a potentially unsustainable business model.

What is the price forecast for ADAP in 2026?

Based on the severe fundamental challenges and high cash burn, ADAP's forecast for 2026 is highly speculative and exceptionally risky. My base case target range is $0.00 to $0.10, reflecting the high probability of continued financial deterioration without a major turnaround, while a bull case scenario—contingent on securing substantial new funding and achieving profitability—could see the stock reach $0.50 to $1.00. Key growth drivers would be the successful commercialization of its pipeline to generate sustainable revenue and a significant reduction in its cash burn rate. The primary assumptions are that the company can navigate its liquidity crisis and that market sentiment does not force a delisting, but the forecast carries extreme uncertainty given the company's current operational inefficiencies and negative cash flows.